News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website


Al Musella`s ASCO Highlights Part 2

Al's Comment:

 Some more of what I feel are the most important reports from ASCO 2020!

Posted on: 05/29/2020

Al Musella's ASCO Highlights Part 2 

  1. Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: A multicenter phase II study   BNCT is a form of radiation therapy.  They are reporting pretty good results for recurrent GBM - 18 months.

  2. SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.   
    This is an experimental vaccine. They report early result that look very good.  PFS of 13.9 months - with Survival at 12 months of 93% for methylated MGMT and 78% for unmethylated MGMT.

  3. Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.  This vaccine is showing promising results -  including a few complete responses which are pretty rare in recurrent GBM!  They report on results on 5 compassionate use patients - so it might be easy to get.
  4. Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma.    Another promising vaccine with one complete response and a few partial responses. Median overall survival was 12 month  which is good for recurrent GBM!


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557